Donnini Serena, Villa Alessandra, Groenhof Gerrit, Mark Alan E, Wierenga Rik K, Juffer André H
The Biocenter Oulu and the Department of Biochemistry, University of Oulu, Oulu, Finland.
Proteins. 2009 Jul;76(1):138-50. doi: 10.1002/prot.22326.
When estimating binding affinities of a ligand, which can exists in multiple forms, for a target molecule, one must consider all possible competing equilibria. Here, a method is presented that estimates the contribution of the protonation equilibria of a ligand in solution to the measured or calculated binding affinity. The method yields a correction to binding constants that are based on the total concentration of inhibitor (the sum of all ionized forms of the inhibitor in solution) to account for the complexed form of the inhibitor only. The method is applied to the calculation of the difference in binding affinity of two inhibitors, 2-phosphoglycolate (PGA) and its phoshonate analog 3-phosphonopropionate (3PP), for the glycolytic enzyme triosephosphate isomerase. Both inhibitors have three titrating sites and exist in solution as a mixture of different forms. In this case the form that actually binds to the enzyme is present at relative low concentrations. The contributions of the alternative forms to the difference in binding energies is estimated by means of molecular dynamics simulations and corrections. The inhibitors undergo a pK(a) shift upon binding that is estimated by ab initio calculations. An interesting finding is that the affinity difference of the two inhibitors is not due to different interactions in the active site of the enzyme, but rather due to the difference in the solvation properties of the inhibitors.
在估算一种可能以多种形式存在的配体与靶分子的结合亲和力时,必须考虑所有可能的竞争平衡。本文提出了一种方法,用于估算溶液中配体的质子化平衡对测量或计算得到的结合亲和力的贡献。该方法对基于抑制剂总浓度(溶液中抑制剂所有离子化形式的总和)的结合常数进行校正,以仅考虑抑制剂的络合形式。该方法应用于计算两种抑制剂2-磷酸乙醇酸(PGA)及其膦酸类似物3-膦酰丙酸(3PP)对糖酵解酶磷酸丙糖异构酶的结合亲和力差异。两种抑制剂都有三个可滴定位点,在溶液中以不同形式的混合物存在。在这种情况下,实际与酶结合的形式以相对较低的浓度存在。通过分子动力学模拟和校正来估算替代形式对结合能差异的贡献。抑制剂结合后会发生pK(a)位移,通过从头计算来估算。一个有趣的发现是,两种抑制剂的亲和力差异不是由于酶活性位点中不同的相互作用,而是由于抑制剂溶剂化性质的差异。